Page 4 - Flipbook

Learning Objectives

1. Management of high risk localized prostate cancer:

is there role for systemic therapy intensification (in

addition to RT+ADT)?

2. Management of de novo mCSPC: what is the

benefit to adding abiraterone and/or prostate RT?

(initial results of the PEACE-1 trial)